{"id":456672,"date":"2021-03-12T06:33:29","date_gmt":"2021-03-12T11:33:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456672"},"modified":"2021-03-12T06:33:29","modified_gmt":"2021-03-12T11:33:29","slug":"veto-t-cell-bone-marrow-transplant-safely-demonstrates-potential-cure-for-sickle-cell-anemia-in-preclinical-trials","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veto-t-cell-bone-marrow-transplant-safely-demonstrates-potential-cure-for-sickle-cell-anemia-in-preclinical-trials\/","title":{"rendered":"Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials"},"content":{"rendered":"
\n

Well-established Mouse Model Utilizes T-cell-depleted, Mismatched Donor Bone Marrow Transplants in Conjunction with Veto T-cell Transplants to Correct Sickle Cell Disease with Minimal Risk as Reported in Bone Marrow Transplantation ( BMT) Journal<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, March 12, 2021<\/span> \/PRNewswire\/ — Cell Source, Inc. (OTC: CLCS) (“<\/span>Cell Source” or the Company”), the world leader in Veto Cell based immunotherapy technologies that can safely facilitate mismatched donor stem cell transplants, e.g. bone marrow transplants (BMT) – in different mouse models for non-malignant hematological disease and organ transplants announced today that its fully mismatched mouse Veto Cell based BMT protocol has overcome significant challenges to durably \u00a0prevent\u00a0 the onset of the pathological parameters of sickle cell disease (SCD) including complete conversion to normal, donor-derived red blood cells.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Cell
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“Sickle cell disease diminishes the quality of life and lowers the life expectancy of approximately 100,000 people in the United States<\/span> alone,” said Dennis Brown<\/span>, Chairman of Cell Source. “The results of the preclinical study published in the BMT Journal demonstrate that our curative approach to SCD may potentially translate to safe and efficacious treatment in human patients. Our Veto Cell based protocol could overcome the lack of suitable donors, treatment toxicities, and graft-related challenges.\u00a0 This may have the potential to deliver a safe, effective, and durable curative treatment for patients with SCD.”<\/p>\n

The study, “Correction of murine sickle cell disease by allogeneic h\u00e6matopoietic cell transplantation with anti-3rd party veto cells,” published online by BMT Journal <\/i>on March 3, 2021<\/span>, may be found here: https:\/\/www.nature.com\/articles\/s41409-021-01237-6<\/a><\/p>\n

As noted in BMT Journal <\/i>, the Veto Cell protocol was able to safely and efficaciously achieve durable, donor-derived chimerism in mice prone to sickle cell disease (i.e., the donor’s transplanted healthy cells begin to be produced by the \u00a0recipient mice instead of the host defective cells) and prevent onset of\u00a0 SCD pathology by overcoming several significant challenges, including:<\/p>\n